Current immunotherapy in rheumatoid arthritis

Immunotherapy

Volumn 5, Issue 9, 2013, Pages 955-974

  Meier, Florian Mp ^a   Frerix, Marc ^a   Hermann, Walter ^a   Müller Ladner, Ulf ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

antirheumatic agent; biological agent; combination therapy; immunotherapy; methotrexate; protein kinase inhibitor; recommendations; rheumatoid arthritis; tofacitinib; treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; AZATHIOPRINE; BUCILLAMINE; CHLOROQUINE; CYCLOSPORIN; DIHYDROFOLATE REDUCTASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; DOXYCYCLINE; ETANERCEPT; FOLIC ACID; FOLINIC ACID; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; PROTEIN KINASE INHIBITOR; RNA; SALAZOSULFAPYRIDINE; THYMIDYLATE SYNTHASE; TOFACITINIB; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; BIOLOGICAL THERAPY; CELL MEMBRANE; CELL TYPE; CYTOKINE PRODUCTION; DISABILITY; DISEASE CONTROL; DNA SYNTHESIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE; MACROPHAGE; META ANALYSIS; MONOTHERAPY; MUCOSAL IRRITATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETINA TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; RNA SYNTHESIS; SKIN IRRITATION; SURVIVAL RATE; SYNOVITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; IMMUNOTHERAPY; INFLAMMATION; SYNOVIAL MEMBRANE;

EID: 84883572611     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.94     Document Type: Review

References (205)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205-2219 (2011).
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376(9746), 1094-1108 (2010).
3. Seger DR, Smith JM Jr, Haltquist ME. Antagonist for pteroylglutamic acid. J. Am. Chem. Soc. 69, 2567 (1947).
4. Kersley GD. Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis. Ann. Rheum. Dis. 27, 64-66 (1968).
5. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000957 (2000).
6. Nakashima-Matsushita N, Homma T, Yu S et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42(8), 1609-1616 (1999).
7. van der Heijden JW, Oerlemans R, Dijkmans BAC et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 60(1), 12-21 (2009).
8. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47(3), 249-255 (2008).
9. Montesinos MC, Desai A, Delano D et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48(1), 240-247 (2003).
10. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J. Rheumatol. 25(1), 36-43 (1998).
11. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann. Intern. Med. 103(4), 489-496 (1985).
12. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312(13), 818-822 (1985).
13. Williams HJ, Willkens RF, Samuelson CO et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 28(7), 721-730 (1985).
14. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J. Rheumatol. 17(12), 1628-1635 (1990).
15. Pinheiro GR, Helfenstein Júnior M, Ferraz MB, Atra E. [A short-term randomized controlled study with methotrexate in rheumatoid arthritis]. Rev. Assoc. Med. Bras. 39(2), 91-94 (1993).
16. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol. 29(8), 1631-1638 (2002).
17. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68(7), 1094-1099 (2009).
18. Braun J, Kästner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, Phase IV trial. Arthritis Rheum. 58(1), 73-81 (2008).
19. Strand V, Cohen S, Schiff M et al. Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. 159(21), 2542-2550 (1999).
20. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
21. de Jong PH, Hazes JM, Barendregt PJ et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. 72(1), 72-78 (2013).
22. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93(3), 198-208 (1999).
23. Hewitson PJ, Debroe S, McBride A, Milne R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J. Clin. Pharm. Ther. 25(4), 295-302 (2000).
24. Osiri M, Shea B, Robinson V et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J. Rheumatol. 30(6), 1182-1190 (2003).
25. Osiri M, Shea B, Robinson V et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 1, CD002047 (2003).
26. Smolen JS, Kalden JR, Scott DL et al. European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353(9149), 259-266 (1999).
27. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39(6), 655-665 (2000).
28. Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. 60(10), 913-923 (2001).
29. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 43(3), 495-505 (2000).
30. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, Phase II study. Arthritis Rheum. 38(11), 1595-1603 (1995).
31. Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 44(9), 1984-1992 (2001).
32. Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50(1), 137-156 (1995).
33. Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br. J. Rheumatol. 36(3), 382-386 (1997).
34. Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int. Immunopharmacol. 2(5), 631-640 (2002).
35. Imai F, Suzuki T, Ishibashi T, Tanaka M, Akiyama Y, Dohi Y. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J. Rheumatol. 21(4), 612-615 (1994).
36. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101(5), 1163-1174 (1998).
37. Akahoshi T, Namai R, Sekiyama N, Tanaka S, Hosaka S, Kondo H. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J. Leukoc. Biol. 62(6), 817-826 (1997).
38. Rodenburg RJ, Ganga A, van Lent PL, van de Putte LB, van Venrooij WJ. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum. 43(9), 1941-1950 (2000).
39. Weinblatt ME, Reda D, Henderson W et al. Sulfasalazine treatment for rheumatoid arthritis: a meta-analysis of 15 randomized trials. J. Rheumatol. 26(10), 2123-2130 (1999).
40. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000958 (2000).
41. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1(8646), 1036-1038 (1989).
42. Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 71(15), 1973-1987 (2011).
43. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 41(2), 196-204 (2002).
44. Hamilton J, McInnes IB, Thomson EA et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann. Rheum. Dis. 60(6), 566-572 (2001).
45. Lehman AJ, Esdaile JM, Klinkhoff AV et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 52(5), 1360-1370 (2005).
46. Burmester GR. [Molecular mechanisms of action of gold in treatment of rheumatoid arthritis - an update]. Zeitschrift für Rheumatologie 60(3), 167-173 (2001).
47. Belsky YP, Ivanova AN, Danilets MG et al. Study of anti-inflammatory action of aurothiomalate, an inhibitor of NF-kB. Bull. Exp. Biol. Med. 151(2), 190-193 (2011).
48. Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum. 62(6), 1650-1659 (2010).
49. Wang ZY, Morinobu A, Kawano S, Saegusa J, Wang B, Kumagai S. Gold sodium thiomalate suppresses the differentiation and function of human dendritic cells from peripheral blood monocytes. Clin. Exp. Rheumatol. 20(5), 683-688 (2002).
50. Clark P, Tugwell P, Bennet K et al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000520 (2000).
51. Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis. 55(3), 169-176 (1996).
52. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 4, CD000959 (2000).
53. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr. Opin. Rheumatol. 23(3), 278-281 (2011).
54. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160(3), 1122-1131 (1998).
55. van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet 335(8688), 539 (1990).
56. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME, Russell AS. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann. Rheum. Dis. 57(10), 582-587 (1998).
57. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 62(6), 775-784 (2010).
58. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68(7), 1086-1093 (2009).
59. van Vollenhoven RF, Geborek P, Forslind K et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379(9827), 1712-1720 (2012).
60. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334(20), 1287-1291 (1996).
61. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(5), 1164-1170 (2002).
62. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 68(7), 1105-1112 (2009).
63. Rantalaiho V, Korpela M, Laasonen L et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res. Ther. 12(3), R122 (2010).
64. Möttönen T, Hannonen P, Leirisalo-Repo M et al. FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353(9164), 1568-1573 (1999).
65. Moreland LW, O'Dell JR, Paulus HE et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis Rheum. 64(9), 2824-2835 (2012).
66. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374(9688), 459-466 (2009).
67. O'Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med. 369(4), 307-318 (2013).
68. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 41(8), 892-898 (2002).
69. Kremer J, Genovese M, Cannon GW et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J. Rheumatol. 31(8), 1521-1531 (2004).
70. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137(9), 726-733 (2002).
71. Alves JA, Fialho SC Morato EF et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev. Bras. Reumatol. 51(2), 141-144 (2011).
72. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 42(7), 1322-1328 (1999).
73. Williams HJ, Ward JR, Reading JC et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 35(3), 259-269 (1992).
74. López-Méndez A, Daniel WW, Reading JC, Ward JR, Alarcón GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum. 36(10), 1364-1369 (1993).
75. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333(3), 137-141 (1995).
76. Stein CM, Pincus T, Yocum D et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum. 40(10), 1843-1851 (1997).
77. Hetland ML, Stengaard-Pedersen K, Junker P et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 54(5), 1401-1409 (2006).
78. Gerards AH, Landewé RB, Prins APA et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann. Rheum. Dis. 62(4), 291-296 (2003).
79. Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J. Rheumatol. 33(3), 486-489 (2006).
80. Haagsma CJ, van Riel PL, de Rooij DJ et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br. J. Rheumatol. 33(11), 1049-1055 (1994).
81. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58(4), 220-225 (1999).
82. Capell HA, Madhok R, Porter DR et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann. Rheum. Dis. 66(2), 235-241 (2007).
83. Ferraz MB, Pinheiro GR, Helfenstein M et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand. J. Rheumatol. 23(5), 231-236 (1994).
84. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 29(10), 2077-2083 (2002).
85. Willkens RF, Urowitz MB, Stablein DM et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 35(8), 849-856 (1992).
86. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum. 38(12), 1799-1806 (1995).
87. O'Dell JR, Elliott JR, Mallek JA et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum. 54(2), 621-627 (2006).
88. Ichikawa Y, Saito T, Yamanaka H et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod. Rheumatol. 15(5), 323-328 (2005).
89. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann. Rheum. Dis. 64(1), 44-51 (2005).
90. Rojkovich B, Hodinka L, Balint G et al. Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. Scand. J. Rheumatol. 28(4), 216-221 (1999).
91. Faarvang KL, Egsmose C, Kryger P, Pødenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann. Rheum. Dis. 52(10), 711-715 (1993).
92. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
93. Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371(9608), 205-214 (2008).
94. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64(5), 625-639 (2012).
95. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun. Rev. 10(10), 631-635 (2011).
96. Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 50(3), 518-531 (2011).
97. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159-167 (2006).
98. Singh JA, Christensen R, Wells GA et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181(11), 787-796 (2009).
99. Desai RJ, Hansen RA, Rao JK et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann. Pharmacother. 46(11), 1491-1505 (2012).
100. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7(1), e30275 (2012).
101. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9(3), 164-172 (2013).
102. Sakai R, Tanaka M, Nanki T et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann. Rheum. Dis. 71(11), 1820-1826 (2012).
103. Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin. Exp. Rheumatol. 30(1), 31-38 (2012).
104. Iannone F, Gremese E, Atzeni F et al. Longterm retention of tumor necrosis factor-a inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J. Rheumatol. 39(6), 1179-1184 (2012).
105. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739-1745 (2009).
106. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50(8), 1445-1452 (2011).
107. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66(7), 921-926 (2007).
108. Bartelds GM, Krieckaert CLM, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14), 1460-1468 (2011).
109. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22-32 (2010).
110. Jobanputra P, Maggs F, Deeming A et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2(6), e001395 (2012).
111. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold- Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand. J. Rheumatol. 36(6), 411-417 (2007).
112. Smolen JS, Kay J, Landewé RB et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann. Rheum. Dis. 71(10), 1671-1679 (2012).
113. Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-a antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140(1), 221-230 (2011).
114. Turkstra E, Ng S-K, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr. Med. Res. Opin. 27(10), 1885-1897 (2011).
115. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2, CD008794 (2011).
116. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2(8613), 706-709 (1988).
117. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 46(7), 1140-1147 (2007).
118. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9(2), R28 (2007).
119. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 58(2), 631-633 (2008).
120. Giampietro C, Ridene M, Lequerre T et al. Anakinra in adult onset still's disease: long term treatment in patients resistant to conventional therapy. Arthritis Care Res. (Hoboken) 65(5), 822-826 (2012).
121. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann. NY Acad. Sci. 1182, 111-123 (2009).
122. Sibley CH, Plass N, Snow J et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 64(7), 2375-2386 (2012).
123. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008).
124. Gabay C, Emery P, van Vollenhoven R. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis(RA): 24-week data from the phase 4 ADACTA trial. Ann. Rheum. Dis. 71(Suppl. 3), 152 (2012).
125. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J. Med. Econ. 15(2), 340-351 (2012).
126. Fujiwara H, Nishimoto N, Hamano Y et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod. Rheumatol. 19(1), 64-68 (2009).
127. Chatzidionysiou K, Lie E, Nasonov E et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann. Rheum. Dis. 71(3), 374-377 (2012).
128. Narváez J, Díaz-Torné C, Ruiz JM et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 41(3), 401-405 (2011).
129. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFa blocker failure. Biologics 6, 191-199 (2012).
130. van Vollenhoven RF, Emery P, Bingham CO et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. (2012) (Epub ahead of print).
131. Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68(9), 1156-1164 (2011).
132. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 64(9), 3043-3051 (2012).
133. Weinblatt ME, Schiff M, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a Phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65(1), 28-38 (2013).
134. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a Phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096-1103 (2008).
135. Guyot P, Taylor PC, Christensen R et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J. Rheumatol. 39(6), 1198-1206 (2012).
136. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int. J. Immunopathol. Pharmacol. 24(1), 269-274 (2011).
137. De Stefano R, Frati E, Nargi F et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin. Rheumatol. 29(5), 517-524 (2010).
138. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
139. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
140. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
141. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized
142. Bergman GJD, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin. Arthritis Rheum. 39(6), 425-441 (2010).
143. Salliot C, Finckh A, Katchamart W et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann. Rheum. Dis. 70(2), 266-271 (2011).
144. Detert J, Bastian H, Listing J et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann. Rheum. Dis. 72(6), 844-850 (2012).
145. Karlsson JA, Neovius M, Nilsson JÅ et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann. Rheum. Dis. (2012) (Epub ahead of print).
146. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375-382 (2008).
147. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
148. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006).
149. Buch MH, Bingham SJ, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum. 50(3), 725-728 (2004).
150. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 51(12), 2252-2261 (2012).
151. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann. Rheum. Dis. 71(8), 1303-1308 (2012).
152. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 6, 429-464 (2012).
153. Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann. Rheum. Dis. 71(2), 225-230 (2012).
154. Nguyen CM, Bounthavong M, Mendes MA et al. Cost utility of tumour necrosis factor-a inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics 30(7), 575-593 (2012).
155. Launois R, Avouac B, Berenbaum F et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J. Rheumatol. 38(5), 835-845 (2011).
156. Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch. Intern. Med. 172(3), 237-244 (2012).
157. Genovese MC, Bojin S, Biagini I et al. Tabalumab in patients with rheumatoid arthritis with an inadequate response to methotrexate and naive to biologic therapy. Arthritis Rheum. 65(4), 880-889 (2013).
158. Teillaud JL. From whole monoclonal antibodies to single domain antibodies: think small. Methods Mol. Biol. 911, 3-13 (2012).
159. Fox DA. Kinase inhibition - a new approach to the treatment of rheumatoid arthritis. N. Engl. J. Med. 367(6), 565-567 (2012).
160. Miossec P. Kinase inhibition in rheumatoid arthritis: a big advance? Lancet 381(9865), 429-431 (2013).
161. Frommer KW, Geyer M, Firestein GS. [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases]. Z. Rheumatol. 71(6), 460-467 (2012).
162. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des. Devel. Ther. 6, 245-250 (2012).
163. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60(2), 317-320 (2009).
164. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 48(9), 2670-2681 (2003).
165. Alten RE, Zerbini C, Jeka S et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann. Rheum. Dis. 69(2), 364-367 (2010).
166. Cohen SB, Cheng TT, Chindalore V et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60(2), 335-344 (2009).
167. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60(5), 1232-1241 (2009).
168. Genovese MC, Cohen SB, Wofsy D et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol. 38(5), 846-854 (2011).
169. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10(4), 356-360 (2009).
170. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69(Suppl. 1), I77-I82 (2010).
171. Guma M, Hammaker D, Topolewski K et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64(9), 2887-2895 (2012).
172. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann. Rheum. Dis. 71(3), 440-447 (2012).
173. Migita K, Komori A, Torigoshi T et al. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res. Ther. 13(3), R72 (2011).
174. Maeshima K, Yamaoka K, Kubo S et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-g and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 64(6), 1790-1798 (2012).
175. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10(1), R14 (2008).
176. Kremer JM, Cohen S, Wilkinson BE et al. A Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64(4), 970-981 (2012).
177. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
178. Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64(3), 617-629 (2012).
179. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 63(8), 1150-1158 (2011).
180. Coombs JH, Bloom BJ, Breedveld FC et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 69(2), 413-416 (2010).
181. Fleischmann R, Kremer J, Cush J et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N. Engl. J. Med. 367(6), 495-507 (2012).
182. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367(6), 508-519 (2012).
183. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised Phase 3 trial. Lancet 381(9865), 451-460 (2013).
184. Wollenhaupt J, Silverfield JC, Lee EB. Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 48 months. Arthritis Rheum. 64(Suppl.10), S548-S549 (2012).
185. Mariette X, Curtis JR, Lee EB. Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme. Ann. Rheum. Dis. 71(Suppl. 3), 199 (2012).
186. Charles-Schoeman C, Wicker P, Sechtem U. Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral JAK inhibitor. Ann. Rheum. Dis. 71(Suppl. 3), 201 (2012).
187. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367(7), 616-624 (2012).
188. Genovese MC, Keystone E, Taylor PC. 24-week results of a blinded Phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), S1049-S1050 (2012).
189. Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366(9), 799-807 (2012).
190. Vanhouette F, Mazur M, van der Aa A. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum. 64(Suppl. 10), S1051 (2012).
191. Zhu T, Oda K, Valluri U. Coadministration of ASP015K, a novel janus kinase inhibitor with methotrexate demonstrates tolerability and lack of pharmaco-kinetic interactions in patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), S569 (2012).
192. Genovese MC, Kavanaugh A, Weinblatt ME et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, Phase I study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63(2), 337-345 (2011).
193. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11), 3309-3318 (2008).
194. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363(14), 1303-1312 (2010).
195. Ishiguro N, Yamamoto K, Katayama K et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol. 23(3), 430-439 (2012).
196. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7(6), 429-442 (2007).
197. Murphy KP. Janeways's Immunobiology (8th Edition). Garland Science, Taylor & Francis Group, LLC, Florence, KY, USA (2012)
198. van der Heijde D, Tanaka Y, Fleischmann R. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month Phase 3 randomized radiographic study. Arthritis Rheum. 65(3), 559-570 (2013).
199. Smolen JS, Aletaha D, Gruben D. Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum. 64(Suppl. 10), S334 (2012).
200. American College of Rheumatology.www.rheumatology.org
201. European League Against Rheumatism.www.eular.org
202. US FDA approval of etanercept for rheumatoid arthritis.www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf
203. US FDA approval of tofacitinib for rheumatoid arthritis.www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm
204. Details of tofacitinib for rheumatoid arthritis by the advisory committee meeting.www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM304200.pdf
205. Study of the effect of fostamatinib twice daily on blood pressure in patients with rheumatoid arthritis (Oskira ABPM). http://clinicaltrials.gov/ show/NCT01563978